Wall Street brokerages forecast that Zoetis Inc (NYSE:ZTS) will report sales of $1.41 billion for the current quarter, according to Zacks. Five analysts have provided estimates for Zoetis’ earnings, with estimates ranging from $1.39 billion to $1.42 billion. Zoetis reported sales of $1.28 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 10.2%. The firm is expected to report its next quarterly earnings results on Thursday, February 15th.
According to Zacks, analysts expect that Zoetis will report full-year sales of $1.41 billion for the current year, with estimates ranging from $5.24 billion to $5.27 billion. For the next financial year, analysts anticipate that the company will post sales of $5.63 billion per share, with estimates ranging from $5.57 billion to $5.69 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Zoetis.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the business earned $0.52 earnings per share. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research report on Thursday, October 12th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a research report on Wednesday, September 6th. BidaskClub lowered Zoetis from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Morgan Stanley upped their target price on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 target price on Zoetis and gave the company a “buy” rating in a research note on Friday, August 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $68.53.
Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. raised its stake in Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after acquiring an additional 230 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new position in Zoetis during the third quarter worth $114,000. Harfst & Associates Inc. raised its stake in Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after acquiring an additional 260 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in Zoetis during the second quarter worth $119,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after acquiring an additional 1,360 shares in the last quarter. Hedge funds and other institutional investors own 93.33% of the company’s stock.
Shares of Zoetis (ZTS) opened at $72.38 on Thursday. Zoetis has a 12-month low of $50.57 and a 12-month high of $72.99. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The firm has a market capitalization of $35,196.84, a P/E ratio of 33.13, a PEG ratio of 2.17 and a beta of 1.06.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. This represents a $0.50 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s dividend payout ratio is currently 22.11%.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect Zoetis Inc (ZTS) Will Post Quarterly Sales of $1.41 Billion” was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.truebluetribune.com/2017/12/14/analysts-expect-zoetis-inc-zts-will-post-quarterly-sales-of-1-41-billion.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.